Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation | Zendy

Gregory W. Albers | Zendy; HansChristoph Diener | Zendy; Lars Frison | Zendy; Margaretha Grind | Zendy; Mark Nevinson | Zendy; Stephen Partridge | Zendy; Jonathan L. Halperin | Zendy; Jay Horrow | Zendy; S. Bertil Olsson | Zendy; Palle Petersen | Zendy; Alec Vahanian | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation

Author(s) -

Gregory W. Albers,

HansChristoph Diener,

Lars Frison,

Margaretha Grind,

Mark Nevinson,

Stephen Partridge,

Jonathan L. Halperin,

Jay Horrow,

S. Bertil Olsson,

Palle Petersen,

Alec Vahanian

Publication year - 2005

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.293.6.690

Subject(s) - medicine , ximelagatran , warfarin , atrial fibrillation , stroke (engine) , confidence interval , clinical endpoint , cardiology , embolism , relative risk , rate ratio , anesthesia , randomized controlled trial , dabigatran , mechanical engineering , engineering

In patients with nonvalvular atrial fibrillation, warfarin prevents ischemic stroke, but dose adjustment, coagulation monitoring, and bleeding limit its use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research